IL2 and autoimmune disease: Therefore, additional well-controlled clinical trials are needed to validate improved and safer dosing strategies for low-dose IL-2 used in autoimmune diseases, but also future studies need to be done both in experimental animal models and later in clinics in order to validate IL-2/anti-cytokine therapies or IL-2/anti-IL-2 complex or IL-2 modification therapies as well.